For decades, the burden of birth control has fallen squarely on women’s shoulders. Pills, patches, IUDs, injections—the list goes on. Meanwhile, men have been relegated to condoms or the nuclear option of vasectomy. But that might finally be changing.
Two main types of male birth control pills are making their way through clinical trials. The hormonal approach includes drugs like 11-beta-MNTDC and dimethandrolone undecanoate. Then there’s the non-hormonal route with YCT-529. Both sound like alphabet soup, but they’re actually showing real promise.
Two promising male birth control approaches are advancing through trials: hormonal drugs and non-hormonal YCT-529, both showing real potential.
The 11-beta-MNTDC pill demonstrated something remarkable in Phase 1 trials—it crushed sperm production while keeping libido intact. Forty healthy men took it daily for 28 days. Their sperm-producing hormones plummeted. The study was conducted by researchers from University of Washington and UCLA at sites in Seattle and Torrance, CA.
Side effects? Mild fatigue, some acne, headaches, and slight decreases in sex drive. Nothing that sent anyone running for the hills. Similar to evidence-based treatments for other conditions, these trials follow rigorous protocols to ensure safety and effectiveness.
YCT-529 takes a different approach entirely. It’s hormone-free and showed 99% effectiveness in preventing pregnancy in male mice within four weeks. The drug just passed its first human safety test with 16 volunteers. No significant side effects detected. The study showed that plasma concentrations peaked with a median time of 8 hours for most doses.
Here’s the kicker—both options appear reversible. Stop taking the pills, and fertility bounces back. Mice recovered in six weeks, primates in 10-15 weeks. The hormonal pills work by mimicking testosterone but at concentrations too low to support sperm production in the testes. Clever, right?
NES/T gel deserves mention too. It’s the first male contraceptive to complete a full year of large-scale human trials. The gel combines Nestorone and testosterone, matching the efficacy of long-acting female contraceptives.
But let’s be real—none of these has reached Phase III trials or FDA approval yet. We’re still in the early stages. The science looks solid, the safety profiles seem manageable, and reversibility appears intact.
Animal studies suggest full fertility recovery after stopping treatment.
